<DOC>
	<DOCNO>NCT01018069</DOCNO>
	<brief_summary>To determine AEG35156 enhance combine complete remission ( CR ) CR incomplete platelet recovery ( CRp ) rate high-dose cytarabine idarubicin AML follow failure single standard dose cytarabine base frontline induction regimen .</brief_summary>
	<brief_title>AEG35156 Combination With High-dose Cytarabine Idarubicin AML Following Failure Single Standard Dose Cytarabine Based Frontline Induction Regimen</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>X-Linked Inhibitor Apoptosis Protein</mesh_term>
	<criteria>Patients AML , except APL ( acute promyelocytic leukemia ) , fail single standard dose cytarabine base frontline induction regimen . The diagnosis refractory AML base presence either &gt; 10 % blast marrow blood 510 % blast either site together cytopenia ( Hb &lt; 10 g/dL , platelet &lt; 100 x 109/L , neutrophil count &lt; 1.0 x 109/L ) . Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . Male , female patient postmenopausal ( amenorrheic least 12 month ) , surgically biologically sterile . Patients must adequate organ immune function indicate follow laboratory value : Parameter Laboratory Values Serum creatinine ; ≤2.0 mg/dL ( ≤ 177 μmol/L Total Bilirubin ≤2.0 mg/dL ( ≤ 34 μmol/L ) AST ( SGOT ) ALT ( SGPT ) ≤3 X ULN The patient must understand , able willing likely fully comply study procedure , include schedule followup , restriction . Clinical evidence ongoing grade 3 4 nonhematological toxicity initial standard dose cytarabinebased induction chemotherapy Patients prior history peripheral neuropathy grade 2 high . Clinical evidence active CNS leukemic involvement . Active uncontrolled infection . Patients infection active treatment antibiotic whose infection control may enter study . Current evidence invasive fungal infection ( blood tissue culture ) . Current evidence active second malignancy except nonmelanoma skin cancer . Uncontrolled medical problem , unrelated malignancy , sufficient severity opinion investigator , impair patient 's ability give inform consent unacceptably reduce safety propose treatment . Neurological psychiatric disorder would interfere consent study followup . Known suspected intolerance hypersensitivity study drug [ closely related compound ] state ingredient . Study drug antisense , cytarabine idarubicin . History alcohol substance abuse within last year . Use another investigational agent within last 14 day prior enrolment . Patients receive previous antisense agent last 90 day exclude . Female patient pregnant , lactating , positive pregnancy test screening must exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Acute</keyword>
	<keyword>myeloid</keyword>
	<keyword>leukemia</keyword>
	<keyword>antisense</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>idarubicin</keyword>
	<keyword>cytarabine</keyword>
	<keyword>Patients AML , except APL ( acute promyelocytic leukemia ) , fail single standard dose cytarabine base frontline induction regimen .</keyword>
</DOC>